Many big pharma companies have ventured into biotechs in the country in search of the next blockbusters in oncologic, cardiometabolic, and autoimmune indications, amongst others. Biosimilars, like Chinese semaglutide, mimic original biologics but may differ in manufacturing, efficacy, and cost, enhancing accessibility. FDA grants approval for Zepzelca + Tecentriq combination in first-line ES-SCLC, offering a new immunotherapy-chemotherapy treatment option. Boehringer Ingelheim’s JASCAYD® (nerandomilast) gains FDA approval for IPF, offering an oral PDE4B inhibitor with favorable tolerability and the first new treatment option in 10+ years.

• Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses.
• Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world’s second largest economy.
• Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Clinical trials and early approvals for diabetes

As Mainland China faces a pressing obesity crisis, the introduction of semaglutide biosimilars is critical. These medications mimic natural hormones, boosting insulin secretion and suppressing appetite, which promotes effective weight loss. The first GLP-1 drug was made by copying a chemical found in the venom of the Gila monster.

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. While it is therefore unclear as to how the Chinese market will play out, given the lack of precedent, patent losses with blockbuster drugs in other disease areas offer a clue. Generics and biosimilars can be on average 80% cheaper, meaning patients often switch away from the more expensive branded alternative.

In China, you can get your hands on Ozempic easily if you know where to look

As researchers continue to discover new potential use cases for GLP-1 drugs, and public interest and demand remains high, these drugs may be on the FDA’s official shortage list for months or even years to come. If the shortage ends, one type of compounding pharmacy (called 503a) would be required to stop production immediately, while 503b pharmacies, which typically produce on a larger scale, would have 60 days. An end to the shortage would require some substantial pivots within this booming cottage industry. None of the telehealth companies that sent compounded semaglutide to WIRED made mention of what might happen in this scenario during the intake process. Mainland China presents an enormous commercial opportunity for drug developers in this space, as the total number of people living with T2D and obesity is the highest anywhere in the world. Clarivate epidemiological forecasts forecast the total obese population in the country to exceed 500 million2 by 2033, suggesting a huge paradigm shift in the way the disease is currently dealt with.

Amid the escalating obesity crisis, particularly oral semaglutide buy in Mainland China, semaglutide has emerged as a pivotal therapeutic option. Developed by Novo Nordisk, this medication now faces competition from innovative biosimilars like Jiyoutai, designed to offer similar benefits at potentially lower costs. Currently, over 11 companies are advancing through clinical trials, indicating a swift market transformation. The recent approval of Wegovy, branded as NovoCare in China, highlights the growing accessibility of semaglutide-based therapies.

Ozempic won approval from China in 2021, and Novo Nordisk saw sales of the drug in the greater China region double to $698 million last year. This study concluded that the use of semaglutide resulted in significant weight loss. In addition, Xi’an Sonwu has a clean and tidy production department with advanced equipment. Under the company’s leadership, researchers continue to develop new products to meet customers’ needs. It’s critical to take note of that semaglutide ought to be utilized as a feature of an exhaustive weight the executives plan that incorporates a decreased calorie diet and expanded actual work. It ought to be recommended and observed by a medical services proficient to guarantee protected and successful use.

In April 2024, a Chinese drugmaker submitted its biosimilar application, marking the beginning of fierce competition against Ozempic. The launch of Wegovy, known as NovoCare in China, adds further complexity to this place. With obesity rates soaring, the demand for effective treatments is rising, driving innovation in biosimilars.

Therapeutic Equivalence of Semaglutide and Its Biosimilars

30iu/3mlSemaglutide Injection pen 0.68mg/ml, 1.5mlInjection pen 1.34mg/ml, 1.5mlInjection pen 1.34mg/ml, 3.0mlraw material. Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Like Ozempic® and Wegovy®, Rybelsus® contains semaglutide as its active ingredient, which is a glucagon-like peptide-1 receptor agonist (GLP-1RA). Compared to injectable medications like Ozempic® (semaglutide once weekly) and Wegovy® (semaglutide once weekly for weight management), Rybelsus® is taken orally once a day. Ozempic is only approved for treating diabetes and not weight loss in China, but e-commerce platforms in the country have made it easy for users to buy the drug by merely stating they have diabetes without presenting proof. Ozempic also sells for much cheaper in China, costing around $139 for a monthly dose on JD.com, the Journal reported, compared to more than $900 in the U.S. without insurance. A gray market for Ozempic is booming in China which has the world’s largest obese population of more than 200 million adults, The Wall Street Journal reported.

Appropriate studies have not been performed on the relationship of age to the effects of Wegovy® in children younger than 12 years of age for weight management and lowering the risk of heart attack or stroke and in children to treat MASH. The first GLP-1RA generic was approved in the US last week when the US Food and Drug Administration (FDA) greenlit Teva’s drug referencing Novo Nordisk’s Saxenda (liraglutide). However, Saxenda is not one of the new-generation weight loss drugs and is far less popular than semaglutide and Lilly’s tirzepatide. Chinese Semaglutide is a biosimilar of Ozempic, aiding weight loss and diabetes management by mimicking GLP-1 hormone effects. The biosimilar development place in China, particularly for semaglutide, is fraught with challenges. Regulatory barriers frequently delay approval processes, obstructing the introduction of affordable alternatives.

Xi’an Sonwu completely makes sure of the product’s quality, so samples can be supplied. But as soon as a bad online pharmacy gets taken down, another two pop up in its place. “So we just continue to do our due diligence, but it’s kind of like you’re on a hamster wheel,” he says. “There are legitimate pharmacies that operate online and I would say probably 5% of all pharmacies that operate online are legitimate,” says Al Carter, NABP’s executive director. Compounding pharmacies are required to source their ingredients from FDA-registered facilities, says Brunner.

This is the most important part of controlling your diabetes, and is necessary if the medicine is to work properly. Also, exercise regularly and test for sugar in your blood or urine as directed. To learn more about key domestic and multinational company drugs launching into the Mainland China marketplace, please download our Drugs to Watch 2024 report. Chinese biotechs are pushing ahead with developing candidates to take advantage of the impending commercial opportunity. GlobalData states that 16 companies are developing generic versions across various clinical phases, with a slew already at Phase III. United Laboratories, Huadong Medicine, and Qilu Pharmaceutical, amongst others, have generic semaglutide assets at this final clinical phase.